GW Pharma cannabis drug gets green light in France
LONDON Oct 21 (Reuters) - GW Pharmaceuticals' cannabis-derived drug Sativex has been recommended for approval in France for the treatment of spasticity due to multiple sclerosis, the drugmaker said on Monday.
Sativex will be sold in France by GW's European partner Almirall following completion of national pricing and reimbursement procedures.
The drug - which is sprayed under the tongue - is currently available in Britain, Spain, Germany, Canada, Denmark, Norway, Israel, Austria, Poland, Sweden, Italy and Finland.
- Citing security threat, Obama expands U.S. role fighting Ebola
- Tesla prevails in top Massachusetts court over direct sales
- Russia needs government investment to avoid recession, says former finance minister
- Boeing, SpaceX win contracts to build 'space taxis' for NASA
- Stocks end higher on bet Fed won't change rate stance